MIRM: Higher FY26 sales guidance meets a pivotal launch and late-stage trial momentum

What happened

Mirum Pharmaceuticals reported Q3 product sales of $185.7 million and raised its FY26 sales guidance to $715 million–$720 million. ATEBRIOZ launched following FDA approval, and positive Phase 3 results for LIVMARLI and brelovitug advanced plans for regulatory submissions.

Confirmed

Global impact / market context

Higher guidance signals that Mirum expects stronger sales, while ATEBRIOZ’s launch creates a route for approved-product revenue. Positive late-stage trial results could support future submissions, but those medicines are not yet described as approved; development and launch costs may also affect cash available.

Analyst inference

The update combines current sales and an increased forecast with two different growth drivers: a newly launched approved medicine and trial results that may support future filings. Investors can distinguish revenue available now from potential revenue that depends on regulatory review and commercial execution.

Analyst inference

What to watch

1. Track whether later reports show sales consistent with the $715 million–$720 million FY26 guidance, since actual revenue will indicate whether the raised forecast is being achieved. Analyst inference
2. Watch for regulatory submissions following the positive LIVMARLI and brelovitug Phase 3 results; submissions are filings asking regulators to review a medicine for approval. Analyst inference
3. Assess whether ATEBRIOZ launch updates provide evidence of growing product sales, while recognizing the supplied article gives no launch revenue or uptake figures. Analyst inference

Evidence

• Original source link unavailable